drugset / Trial / NCT01847118
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors. The secondary objective is to explore the preliminary anti-tumor effects.
Timeline
- Start
- 2013-04
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Suvemcitug | Monoclonal antibody | 2 mg/kg | — |
| Subject | Suvemcitug | Monoclonal antibody | 5 mg/kg | — |
| Subject | Suvemcitug | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Suvemcitug | Monoclonal antibody | 10 mg/kg | — |
| Subject | Suvemcitug | Monoclonal antibody | 12.5 mg/kg | — |
| Subject | Suvemcitug | Monoclonal antibody | 15 mg/kg | — |